AstraZeneca PLC
Discovers, develops, manufactures and commercialises prescription medicines across oncology, cardiovascular, respiratory, immunology, vaccines and rare disease therapies.
As of Oct 14, 2026
Summary
AstraZeneca is a multinational pharmaceutical company focused on oncology, cardiovascular, respiratory, and immunology treatments. The stock is trading at 11,896p with a bearish technical lean, having declined 1.1 percent today and 5.0 percent over the past year. The company carries a market capitalisation of £187 billion.
Price history
As of Oct 13, 2026
Performance
+3.40%
-0.52%
-2.12%
-4.70%
-12.26%
-5.01%
As of Oct 13, 2026
Technical indicators
- 44.1
- -36.93Bearish
- 50: 12052.1 · 200: 13404.12Bearish
- 11,720p / 12,180p
Technical Bias
Bearish lean
AstraZeneca is trading at 11,896p between support at 11,720p and resistance at 12,180p. The technical picture leans bearish: MACD is negative at -36.93 and the price sits below both its 50-day and 200-day moving averages, suggesting downward momentum. RSI at 44.1 is neutral. This is a derived technical read, not investment advice.
A transparent read of the indicators below — not a prediction or recommendation.
As of Oct 13, 2026
Fundamentals
- £187B
- 24.1
- 4.99p
- 17.02%
- +6.4%
- £8.67B
- 0.21
- 9,827p – 15,468p
- 1.99%
- Aug 6, 2026
- Oct 30, 2026 (15 days)
As of Oct 14, 2026
Upcoming catalysts
- Earnings report
As of Oct 14, 2026
Latest news
As of Oct 14, 2026
MonkeyTrade's Take on AstraZeneca PLC
Short-term outlook
The short-term setup leans bearish: AstraZeneca trades below both its 50-day (12,052.1p) and 200-day (13,404.12p) moving averages, MACD confirms downward momentum, and shares are down 2.1% over the past month. RSI at 44.1 is neutral, leaving room for further weakness. A break below 11,720p support would reinforce the bearish read, while a move through 12,180p resistance would challenge it. No earnings catalyst is imminent, with the next report not due until October 2026.
Medium-term outlook
AstraZeneca's fundamentals look solid for the medium term: revenue growing 6.4% year-on-year, a healthy 17% profit margin, and a 2.0% dividend yield, all wrapped in a premium valuation at 24.1x earnings. Yet the technical lean is bearish, suggesting the market isn't yet rewarding that quality story with upward momentum. A shift in technical bias toward bullish would be the key signal that sentiment is catching up with the fundamentals.
Key risks
- Shares currently sit well below the 52-week high of 15,468p, having traded as low as 9,827p over the past year, which shows the stock can swing significantly despite its low beta of 0.21.
- A price-to-earnings ratio of 24.1 means investors are paying a premium relative to current earnings, leaving less room for error if growth slows.
- Heavy investment in new ventures, such as the $1 billion R&D centre in Kendall Square and AI-driven biologics partnerships, carries execution risk and could weigh on near-term profitability before any returns materialise.
- Revenue growth of 6.4% year-on-year is solid but must be sustained to justify the current valuation, particularly in a competitive healthcare sector where peers are also pushing into AI-driven drug discovery.
About AstraZeneca PLC
AstraZeneca PLC is a major pharmaceutical manufacturer listed on the London Stock Exchange under the ticker AZN. Operating within the healthcare sector, the company sits in the drug manufacturers general industry, reflecting a broad portfolio rather than a single-therapy focus. With a market capitalisation of £187B, AstraZeneca ranks among the larger names on the LSE, giving it significant weight within healthcare-focused indices and portfolios.
The company's key figures offer a snapshot of how the market currently views its shares. A price-to-earnings ratio of 24.1 shows what investors are paying relative to AstraZeneca's earnings, while a dividend yield of +2.0% reflects the income return shareholders receive relative to the share price. Together, these figures give readers a starting point for understanding how AstraZeneca is valued and rewarded compared with its own history and the wider healthcare sector.
How to trade AstraZeneca PLC
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.